药物输送设备的全球市场:现状分析与预测(2022年～2028年)

全球药物输送设备的市场规模，在预测期间内预计以约6％的年复合成长率成长。糖尿病患者增加，癌症和呼吸疾病盛行率增加，生技药品增加，药物输送相关的技术进步，促进市场成长。

本报告提供全球药物输送设备市场的相关调查，市场洞察，市场趋势，竞争模式，企业概要等全面性资讯。

目录

第1章 市场简介

• 市场定义
• 主要的目标
• 相关利益者
• 限制

第2章 调查手法或假设

• 药物输送设备市场调查流程
• 药物输送设备市场调查手法
• 受访者简介

第3章 市场摘要

第4章 摘要整理

第5章 COVID-19对药物输送设备市场的影响

第6章 药物输送设备市场收益(10亿美元)(2020年～2028年)

第7章 市场洞察:各类型

• 注射
• 吸入器
• 其他

第8章 市场洞察:各技术

• Bluetooth
• NFC
• 其他

第9章 市场洞察:各用途

• 肿瘤
• 感染疾病
• 呼吸疾病
• 糖尿病
• 其他

第10章 市场洞察:各地区

• 北美
  • 美国
  • 加拿大
  • 其他的北美
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他的欧洲
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他的亚太地区
• 全球其他地区

第11章 药物输送设备的市场动态

• 推动市场要素
• 市场课题
• 影响分析

第12章 药物输送设备的市场机会

第13章 药物输送设备的市场趋势

第14章 需求面和供给方面的分析

• 需求面分析
• 供给面

第15章 价值链分析

第16章 竞争模式

• 竞争情形
  • 波特的五力分析

第17章 企业概要

• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• F. Hoffmann-La Roche Ltd
• Novartis AG
• BD
• Bayer AG
• uniQure NV.
• SIBIONO
• GSK plc.
• Amgen Inc.

第18章 免责声明

Drug delivery devices are specialized tools made for a specific route of drug or therapeutic material administration. The devices are used once or more during medical procedures. Drug delivery devices present unique challenges in many areas of product development, such as regulatory strategy, design, and material considerations, as well as the creation and use of testing protocols. When providing pharmacological compounds that have therapeutic benefits in humans or animals, drug delivery devices are a crucial component. Growth in the number of diabetic patients as well as an increase in the prevalence of cancer and respiratory ailments are driving an increase in the use of drug delivery systems among patients and professionals. Moreover, in March 2021 researchers from Stanford University and the University of North Carolina at Chapel Hill (UNC) created a 3D-printed vaccine patch that they claim offers superior protection to a conventional vaccine shot. The creation of such innovative items is encouraging the use of medicine delivery products and fosters market expansion.

The Drug Delivery Devices Market is expected to grow at a steady rate of around 6% owing to the rising incidence of chronic and acute diseases, rising growth of biologics, rising technological advancements related to drug delivery devices, rising number of diabetes patients, and rising prevalence of cancer patients. Moreover, a large number of products available in the drug delivery industry are further creating opportunities for the key market players. For instance, Coalesce Product Development Limited, a UK-based drug delivery device development business that Novartis Sandoz acquired, is creating a variety of inhalation devices. This comprises updated models of breath-actuated inhalers, pre-metered dry powder inhalers, and pressurized metered dose inhalers.

Based on type, the market is segmented into injectable devices, inhalation devices, and others. The injectable segment witnessed a substantial CAGR during the 2021 period owing to the increasing demand for injectable systems such as syringes for drug delivery. Furthermore, the entry of global players into emerging markets adds to the growth of the market. For instance, BD announced that it has received pandemic orders worldwide for needles and syringes, totaling 2 billion injection devices to support COVID-19 vaccination efforts. Such high demand for syringes and needles is expected to boost the segmental growth till the vaccination gets over.

On the basis of technology, the market is categorized into bluetooth, NFC, and others. Among these, the bluetooth segment captured a significant share of the market in 2020 owing to higher utilization of the technology in order to connect drug delivery devices to smartphones. Additionally, greater bluetooth technology compatibility with other drug delivery devices and simplicity of use are anticipated to fuel the bluetooth sub-segment growth over the course of the projection period.

Based on application, the drug delivery devices market has been classified into oncology, infectious diseases, respiratory diseases, diabetes, and others. The diabetes segment is to witness higher adoption of drug devices during the forecast period. This is mainly due to increasing cases of diabetes patients all across the world. For instance, 34.2 million Americans have diabetes in 2018, of whom 26.8 million had a diagnosis and 7.3 million had been underdiagnosed, according to the American Diabetes Association (ADA). The adoption of drug delivery devices in the field of diabetes is therefore anticipated to be influenced by the rising number of cases of diabetes that have been diagnosed.

For a better understanding of the market adoption of the drug delivery devices industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. The main reasons for this region's growth include the existence of important market participants, highly developed healthcare infrastructure and spending, and strategic partnerships. Along with this, it is predicted that throughout the forecast period, the prevalence of chronic diseases in the U.S. and a growing emphasis on preventative care will fuel market expansion in this region. According to the American Cancer Society's 2022 report, 1.9 million new cases of cancer are anticipated to be diagnosed in the United States in 2022, and cancer cases are further anticipated to rise in the nation. As a result, demand for drug-delivery devices for various therapeutics is anticipated to rise in the region due to the high mortality rate associated with the disease.

Some of the major players operating in the market include: Pfizer, Inc.; Johnson & Johnson Services, Inc.; F. Hoffmann-La Roche, Ltd.; Novartis AG; BD; Bayer AG; uniQure N.V.; SIBIONO; GSK plc.; Amgen Inc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Drug Delivery Devices Market
• 2.2. Research Methodology of the Drug Delivery Devices Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE DRUG DELIVERY DEVICES MARKET

6 DRUG DELIVERY DEVICES MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY TYPE

• 7.1. Injectable Devices
• 7.2. Inhalation Devices
• 7.3. Others

8 MARKET INSIGHTS BY TECHNOLOGY

• 8.1. Bluetooth
• 8.2. NFC
• 8.3. Others

9 MARKET INSIGHTS BY APPLICATION

• 9.1. Oncology
• 9.2. Infectious Diseases
• 9.3. Respiratory Diseases
• 9.4. Diabetes
• 9.5. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 DRUG DELIVERY DEVICES MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 DRUG DELIVERY DEVICES MARKET OPPORTUNITIES

13 DRUG DELIVERY DEVICES MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1 Pfizer Inc.
• 17.2 Johnson & Johnson Services, Inc.
• 17.3 F. Hoffmann-La Roche Ltd
• 17.4 Novartis AG
• 17.5 BD
• 17.6 Bayer AG
• 17.7 uniQure NV.
• 17.8 SIBIONO
• 17.9 GSK plc.
• 17.1 Amgen Inc.

18 DISCLAIMER